Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056

Hye Ryun Kim, Joung Soon Jang, Jong Mu Sun, Myung Ju Ahn, Dong Wan Kim, Inkyung Jung, Ki Hyeong Lee, Joo Hang Kim, Dae Ho Lee, Sang We Kim, Byoung Chul Cho

Research output: Contribution to journalComment/debate

Abstract

Present: The current funding information is incomplete. Correct: The complete funding information is given below.

Original languageEnglish
Number of pages1
JournalOncotarget
Volume8
Issue number33
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
nimotuzumab
gefitinib

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Hye Ryun ; Jang, Joung Soon ; Sun, Jong Mu ; Ahn, Myung Ju ; Kim, Dong Wan ; Jung, Inkyung ; Lee, Ki Hyeong ; Kim, Joo Hang ; Lee, Dae Ho ; Kim, Sang We ; Cho, Byoung Chul. / Correction : A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056. In: Oncotarget. 2017 ; Vol. 8, No. 33.
@article{9188174309ad49b1a302f46538984152,
title = "Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056",
abstract = "Present: The current funding information is incomplete. Correct: The complete funding information is given below.",
author = "Kim, {Hye Ryun} and Jang, {Joung Soon} and Sun, {Jong Mu} and Ahn, {Myung Ju} and Kim, {Dong Wan} and Inkyung Jung and Lee, {Ki Hyeong} and Kim, {Joo Hang} and Lee, {Dae Ho} and Kim, {Sang We} and Cho, {Byoung Chul}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20268",
language = "English",
volume = "8",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "33",

}

Correction : A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056. / Kim, Hye Ryun; Jang, Joung Soon; Sun, Jong Mu; Ahn, Myung Ju; Kim, Dong Wan; Jung, Inkyung; Lee, Ki Hyeong; Kim, Joo Hang; Lee, Dae Ho; Kim, Sang We; Cho, Byoung Chul.

In: Oncotarget, Vol. 8, No. 33, 01.01.2017.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Correction

T2 - A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) [Oncotarget, 8, (2017) (15943-15951)] DOI: 10.18632/oncotarget.13056

AU - Kim, Hye Ryun

AU - Jang, Joung Soon

AU - Sun, Jong Mu

AU - Ahn, Myung Ju

AU - Kim, Dong Wan

AU - Jung, Inkyung

AU - Lee, Ki Hyeong

AU - Kim, Joo Hang

AU - Lee, Dae Ho

AU - Kim, Sang We

AU - Cho, Byoung Chul

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Present: The current funding information is incomplete. Correct: The complete funding information is given below.

AB - Present: The current funding information is incomplete. Correct: The complete funding information is given below.

UR - http://www.scopus.com/inward/record.url?scp=85029092649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029092649&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20268

DO - 10.18632/oncotarget.20268

M3 - Comment/debate

AN - SCOPUS:85029092649

VL - 8

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 33

ER -